Lentivirus Gene Therapy for Farber Disease in NHPs
慢病毒基因治疗 NHP 法伯病
基本信息
- 批准号:7334949
- 负责人:
- 金额:$ 5.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-15 至 2008-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcerAddressAnimal ModelAnimalsAreaBiological AssayBone MarrowBone Marrow TransplantationBrainCalculiCell TransplantsCell surfaceCellsCessation of lifeClinicalComplementComplementary DNAComplexCultured CellsDevelopmentDiseaseEngineeringEngraftmentEnzymesEventFabry DiseaseFarber&aposs lipogranulomatosisGaucher DiseaseGene TransferGene-ModifiedGenesGerm LinesGlycoproteinsGranulomaHealthHeartHumanHydrolaseIn VitroInfectionInflammationKineticsMacaca mulattaMediatingMetabolicMicrogliaModelingNeurologicNumbersOutcomePainPatientsPolymerase Chain ReactionProtein OverexpressionProtocols documentationRecombinantsReportingResearchResearch ProposalsRetroviridaeSiteStem cellsSubfamily lentivirinaeSystemTestingTherapeuticTimeToxic effectTrainingTropismUniversitiesVesicular stomatitis Indiana viruscellular engineeringcellular transductionclinically relevantearly childhoodenzyme replacement therapygalactosylgalactosylglucosylceramidasegene therapyimplantable devicein vivo Modelmedinnonhuman primatenovelprogramsprotocol developmentresearch studystemsuccessvector
项目摘要
Lysosomal storage disorders (LSDs) are excellent objectives for gene therapy. Target cells for correction are
often are accessible and for many LSDs a phenomenon called 'metabolic cooperativity' occurs. Here cells
that overexpress corrective lysosomai enzymes secrete these hydrolases, which can be functionally utilized
by unmodified bystander cells. Thus lower efficiencies or directed gene transfer to single sites can still effect
systemic correction. Farber disease (FD) is a very severe LSD due to a deficiency in acid ceramidase. FD
presents with debilitating manifestations including painful granulomas and pronounced neurological
consequences. Death often occurs in early childhood. Current treatment for FD, like for many LSDs, is only
palliative. For some LSDs, BMT using unmodified cells has been partially corrective, although little impact on
CMS manifestations has been observed. For only the most prevalent LSDs, enzyme replacement therapy is
an option. Gene therapy using a variety of delivery systems has also been tested in vitro and in in vivo
models of LSDs. A few clinical gene therapy protocols addressing LSDs have also been initiated. No
toxicities were reported although clinical improvements have also not been realized. Previously we
demonstrated the first conceptual possibility that gene therapy could ameliorate FD. Lately, we have been
adapting lentiviruses (LV) for gene augmentation strategies. We have tested successful outcomes using LVs
in cell culture and in small animal models for Fabry disease; another LSD. Yet despite this conceptual
success, and notwithstanding the growing number of small animal models of LSDs, these experiments are
not often predictive of clinical gene therapy outcomes. Thus we have recently initiated gene therapy studies
here at the UHN in non-human primates (NHPs) to better predict outcomes in patients and to identify areas
wherein more research or protocol development is warranted. This proposed study would thus be the first to
fully test LV-mediatedcorrection for an LSD in a more clinically relevant model; that of NHPs.
溶酶体贮积症(lsd)是基因治疗的理想目标。校正的靶细胞是
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates.
非人灵长类动物中慢载体/酸性神经酰胺酶转导的造血细胞的自体移植。
- DOI:10.1089/hum.2010.195
- 发表时间:2011
- 期刊:
- 影响因子:4.2
- 作者:Walia,JagdeepS;Neschadim,Anton;Lopez-Perez,Orlay;Alayoubi,Abdulfatah;Fan,Xin;Carpentier,Stephane;Madden,Melissa;Lee,Chyan-Jang;Cheung,Fred;Jaffray,DavidA;Levade,Thierry;McCart,JAndrea;Medin,JeffreyA
- 通讯作者:Medin,JeffreyA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY A MEDIN其他文献
JEFFREY A MEDIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY A MEDIN', 18)}}的其他基金
Genetic Correction of a Novel "Knock-in" Mouse Model for Farber Disease
法伯病新型“敲入”小鼠模型的基因校正
- 批准号:
8426987 - 财政年份:2013
- 资助金额:
$ 5.4万 - 项目类别:
Genetic Correction of a Novel "Knock-in" Mouse Model for Farber Disease
法伯病新型“敲入”小鼠模型的基因校正
- 批准号:
8598114 - 财政年份:2013
- 资助金额:
$ 5.4万 - 项目类别:
Lentivirus Gene Therapy for Farber Disease in NHPs
慢病毒基因治疗 NHP 法伯病
- 批准号:
6909519 - 财政年份:2005
- 资助金额:
$ 5.4万 - 项目类别:
Lentivirus Gene Therapy for Farber Disease in NHPs
慢病毒基因治疗 NHP 法伯病
- 批准号:
7219737 - 财政年份:2005
- 资助金额:
$ 5.4万 - 项目类别:
Lentivirus Gene Therapy for Farber Disease in NHPs
慢病毒基因治疗 NHP 法伯病
- 批准号:
7092043 - 财政年份:2005
- 资助金额:
$ 5.4万 - 项目类别:
Enhancement of Gene Therapy Outcomes for Fabry Disease
提高法布里病的基因治疗效果
- 批准号:
6660318 - 财政年份:2001
- 资助金额:
$ 5.4万 - 项目类别:
Enhancement of Gene Therapy Outcomes for Fabry Disease
提高法布里病的基因治疗效果
- 批准号:
6501309 - 财政年份:2001
- 资助金额:
$ 5.4万 - 项目类别:
Enhancement of Gene Therapy Outcomes for Fabry Disease
提高法布里病的基因治疗效果
- 批准号:
6528362 - 财政年份:2001
- 资助金额:
$ 5.4万 - 项目类别:
Enhancement of Gene Therapy Outcomes for Fabry Disease
提高法布里病的基因治疗效果
- 批准号:
6797751 - 财政年份:2001
- 资助金额:
$ 5.4万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Research Grant














{{item.name}}会员




